IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
February 14, 2023 19:41 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal...
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
February 08, 2023 08:30 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia...
IGC Receives No Objection Letter from Health Canada
January 04, 2023 08:00 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection...
IGC Announces Updated Life Sciences Presentation
December 20, 2022 08:30 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with...
DAVOS ALZHEIMER’S COLLABORATIVE PUBLISHES FRAMEWORK FOR COLLECTIVE ACTION ON ALZHEIMER’S DISEASE HEALTHCARE SYSTEM PREPAREDNESS
December 09, 2022 11:35 ET
|
Davos Alzheimer's Collaborative
New York, NY, Dec. 09, 2022 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), the organization leading an unprecedented global response to Alzheimer’s, today announced publication of a...
IGC to Present at the RHK 2022 Disruptive Growth Conference
November 30, 2022 11:19 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be...
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
October 21, 2021 07:00 ET
|
reMYND
Press release reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase Leuven Belgium, 21 October 2021: reMYND...
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Athira Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ATHA
August 06, 2021 12:45 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant...
ATHA INVESTOR NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Athira Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ATHA
July 29, 2021 12:15 ET
|
The Rosen Law Firm PA
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or...
Alzheimer’s Disease Treatment Market Value Predicted To Reach US$ 5,647.5 Million By 2027: Acumen Research And Consulting
April 07, 2021 10:12 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Alzheimer’s Disease Treatment Market– Global Industry Analysis, Market Size,...